- Home
- Editorial
- News
- Practice Guidelines
- Anesthesiology Guidelines
- Cancer Guidelines
- Cardiac Sciences Guidelines
- Critical Care Guidelines
- Dentistry Guidelines
- Dermatology Guidelines
- Diabetes and Endo Guidelines
- Diagnostics Guidelines
- ENT Guidelines
- Featured Practice Guidelines
- Gastroenterology Guidelines
- Geriatrics Guidelines
- Medicine Guidelines
- Nephrology Guidelines
- Neurosciences Guidelines
- Obs and Gynae Guidelines
- Ophthalmology Guidelines
- Orthopaedics Guidelines
- Paediatrics Guidelines
- Psychiatry Guidelines
- Pulmonology Guidelines
- Radiology Guidelines
- Surgery Guidelines
- Urology Guidelines
Vaccine may replace blood thinners to reduce stroke recurrence
People who have had a stroke caused by a blood clot (ischemic strokes) often need to take medications that make their blood less likely to clot, which helps prevent another stroke. Now, a new study published in the journal Hypertension suggests that vaccine might replace oral blood thinners to reduce secondary stroke risk caused by blood clots, without triggering an autoimmune response or increasing the risk of serious bleeding.
The vaccine, S100A9, inhibits blood clot formation and, during the study, protected the arteries of treated mice from forming new clots for more than two months, and additionally, worked as well as the oral blood thinner clopidogrel in a major artery, according to Hironori Nakagami, study co-author and professor at Osaka University, in Japan.
Also Read: Healthy lifestyle offsets genetic risk of Stroke
"Developing a vaccine to replace and/or compliment daily, oral medications might save many lives and help prevent both secondary strokes and possibly heart attacks," Nakagami said in a press release.
"Many stroke patients don't take their blood thinning drugs as prescribed, which makes it more likely they will have another stroke. This vaccine might one day help solve this issue since it would only need to be injected periodically," Nakagami said.
"We are continuing our research in hopes of being able to start clinical trials between five and ten years from now, but there are differences between mice and humans in how the vaccine will be recognized by the immune system," he said. "We should be able to overcome such problems and believe this vaccine provides a very promising strategy in the secondary prevention of stroke."
For further reference log on to https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.118.11316
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd